GNOM vs. XLV
GNOM (Global X Genomics & Biotechnology ETF) and XLV (State Street Health Care Select Sector SPDR ETF) are both Health & Biotech Equities funds - GNOM tracks the Solactive Genomics Index while XLV tracks the Health Care Select Sector Index. Both are passively managed. Over the past 5 years, GNOM returned -9.59%/yr vs 6.19%/yr for XLV. A 0.53 correlation means they provide meaningful diversification when combined. GNOM charges 0.50%/yr vs 0.08%/yr for XLV.
Performance
GNOM vs. XLV - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GNOM achieves a 11.56% return, which is significantly higher than XLV's -1.35% return.
GNOM
- 1D
- 3.47%
- 1M
- 11.33%
- YTD
- 11.56%
- 6M
- 9.34%
- 1Y
- 57.90%
- 3Y*
- 0.45%
- 5Y*
- -9.59%
- 10Y*
- —
XLV
- 1D
- 3.07%
- 1M
- 4.67%
- YTD
- -1.35%
- 6M
- -0.35%
- 1Y
- 16.13%
- 3Y*
- 6.92%
- 5Y*
- 6.19%
- 10Y*
- 9.48%
GNOM vs. XLV - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
GNOM Global X Genomics & Biotechnology ETF | 11.56% | 18.65% | -15.99% | -8.63% | -36.27% | -15.93% | 51.52% | 1.56% |
XLV State Street Health Care Select Sector SPDR ETF | -1.35% | 14.50% | 2.47% | 2.07% | -2.08% | 26.04% | 13.30% | 13.13% |
Correlation
The correlation between GNOM and XLV is 0.56, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.56 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.52 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.53 |
Correlation (All Time) Calculated using the full available price history since Apr 11, 2019 | 0.53 |
The correlation between GNOM and XLV has been stable across timeframes, ranging from 0.52 to 0.56 - a consistent structural relationship.
GNOM vs. XLV - Sectors Allocation Comparison
Sectors
GNOM
XLV
Healthcare
Technology
-
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Financial Services
-
-
Industrials
-
-
Real Estate
-
-
Utilities
-
-
Healthcare
GNOM
XLV
Technology
GNOM
XLV
-
Basic Materials
GNOM
-
XLV
-
Communication Services
GNOM
-
XLV
-
Consumer Cyclical
GNOM
-
XLV
-
Consumer Defensive
GNOM
-
XLV
-
Energy
GNOM
-
XLV
-
Financial Services
GNOM
-
XLV
-
Industrials
GNOM
-
XLV
-
Real Estate
GNOM
-
XLV
-
Utilities
GNOM
-
XLV
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GNOM vs. XLV — Risk / Return Rank
GNOM
XLV
GNOM vs. XLV - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology ETF (GNOM) and State Street Health Care Select Sector SPDR ETF (XLV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| GNOM | XLV | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.10 | ||
| Sortino ratioReturn per unit of downside risk | +1.34 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.19 | +0.16 |
| Calmar ratioReturn relative to maximum drawdown | 3.20 | 1.55 | +1.65 |
| Martin ratioReturn relative to average drawdown | 9.21 | 3.73 | +5.48 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| GNOM | XLV | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.18 | 1.08 | +1.10 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.29 | 0.42 | -0.71 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.57 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.07 | 0.46 | -0.54 |
Drawdowns
GNOM vs. XLV - Drawdown Comparison
The maximum GNOM drawdown since its inception was -75.00%, which is greater than XLV's maximum drawdown of -39.17%. Use the drawdown chart below to compare losses from any high point for GNOM and XLV.
Loading charts...
Drawdown Indicators
| GNOM | XLV | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -75.00% | -39.17% | -35.83% |
Max Drawdown (1Y)Largest decline over 1 year | -18.17% | -10.47% | -7.70% |
Max Drawdown (3Y)Largest decline over 3 years | -46.47% | -17.11% | -29.36% |
Max Drawdown (5Y)Largest decline over 5 years | -72.29% | -17.11% | -55.18% |
Max Drawdown (10Y)Largest decline over 10 years | — | -28.40% | — |
Current DrawdownCurrent decline from peak | -53.90% | -4.68% | -49.22% |
Average DrawdownAverage peak-to-trough decline | -40.56% | -7.12% | -33.44% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.30% | 4.33% | +1.97% |
Volatility
GNOM vs. XLV - Volatility Comparison
Global X Genomics & Biotechnology ETF (GNOM) has a higher volatility of 8.77% compared to State Street Health Care Select Sector SPDR ETF (XLV) at 5.04%. This indicates that GNOM's price experiences larger fluctuations and is considered to be riskier than XLV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GNOM | XLV | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.77% | 5.04% | +3.73% |
Volatility (6M)Calculated over the trailing 6-month period | 19.72% | 10.67% | +9.05% |
Volatility (1Y)Calculated over the trailing 1-year period | 26.66% | 14.97% | +11.69% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.61% | 14.76% | +18.85% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 34.19% | 16.57% | +17.62% |
GNOM vs. XLV - Expense Ratio Comparison
GNOM has a 0.50% expense ratio, which is higher than XLV's 0.08% expense ratio.
Dividends
GNOM vs. XLV - Dividend Comparison
GNOM's dividend yield for the trailing twelve months is around 1.23%, less than XLV's 1.65% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GNOM Global X Genomics & Biotechnology ETF | 1.23% | 1.37% | 0.00% | 0.00% | 0.00% | 0.03% | 0.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XLV State Street Health Care Select Sector SPDR ETF | 1.65% | 1.60% | 1.67% | 1.59% | 1.47% | 1.33% | 1.49% | 2.17% | 1.57% | 1.47% | 1.60% | 1.43% |
Frequently Asked Questions
GNOM and XLV have a correlation of 0.56, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GNOM has higher volatility (8.77%) compared to XLV (5.04%). In terms of maximum drawdown, GNOM dropped -75.00% vs XLV's -39.17%.
On 5-year performance, XLV leads with 6.19% vs -9.59% for GNOM. On fees, XLV is cheaper at 0.08% per year. On volatility, XLV has been the lower-risk option at 5.04%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, XLV has performed better with a 6.19% return vs -9.59%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
XLV is cheaper with a 0.08% expense ratio, compared with 0.50% for GNOM.
XLV has the higher dividend yield at 1.65%, compared with 1.23% for GNOM.
GNOM tracks Solactive Genomics Index, while XLV tracks Health Care Select Sector Index. They also come from different issuers: Global X and State Street. Their fees differ too: 0.50% for GNOM and 0.08% for XLV.
GNOM currently has the higher Sharpe Ratio (2.18 vs 1.08), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GNOM and XLV
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer